| 产品描述： | PQR620 是一种新型的、选择性的、口服可生物利用的、具有脑渗透性的 TORC1/2 的双重抑制剂。PQR620 在56种淋巴瘤模型检测中具有抗肿瘤活性，处理72小时的平均IC50值为250 nM。 |
| 靶点： |
TORC1(Cell-based assay):250 nM; TORC2(Cell-free assay):250 nM;mTOR |
| 体内研究： |
PQR620 has in vivo anti-lymphoma activity and in vivo synergism with the BCL2 inhibitor venetoclax. The combination of PQR620 and venetoclax have stronger in vivo anti-tumor activity than the single agents in a xenograft model of GCB-DLBCL |
| 细胞实验： |
Cell lines: 56 lymphoma cell lines, ABC-DLBCL cell lines (TMD8, Ri-1), GCB-DLBCL cell lines (OCI-LY-1,SU-DHL-6, DoHH2) Concentrations: 2 μM Incubation Time: 24 h, 72 h Method: PQR620 is dissolved in dimethyl sulphoxide (DMSO) to obtain a stock concentration of 10 mM. PQR620 is assessed in a large panel of cell lines (n = 56) derived from lymphomas. Cell lines are treated with 2 μM PQR620 for 24 h or DMSO as control. |
| 动物实验： |
Animal Models: NOD-Scid mice with RI-1/SU-DHL-6 xenograft Dosages: 50 mg/kg, 100 mg/kg Administration: Oral gavage |
| 参考文献： |
1. Tarantelli C, et al. Cancers (Basel). 2019 Jun 4;11(6). |
| 溶解性： |
Soluble in DMSO、Ethanol |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.245 ml |
11.224 ml |
22.448 ml |
| 5 mM |
0.449 ml |
2.245 ml |
4.49 ml |
| 10 mM |
0.224 ml |
1.122 ml |
2.245 ml |
| 50 mM |
0.045 ml |
0.224 ml |
0.449 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京